KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Total Current Liabilities (2016 - 2025)

Resmed (RMD) has disclosed Total Current Liabilities for 16 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 46.5% year-over-year to $1.2 billion, compared with a TTM value of $1.2 billion through Dec 2025, up 46.5%, and an annual FY2025 reading of $1.0 billion, up 11.91% over the prior year.
  • Total Current Liabilities was $1.2 billion for Q4 2025 at Resmed, down from $1.3 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.3 billion in Q3 2025 and bottomed at $621.1 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $838.7 million, with a median of $771.9 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities surged 58.93% in 2021, then dropped 24.4% in 2022.
  • Year by year, Total Current Liabilities stood at $621.1 million in 2021, then grew by 17.98% to $732.7 million in 2022, then grew by 4.28% to $764.1 million in 2023, then rose by 11.5% to $852.0 million in 2024, then surged by 46.5% to $1.2 billion in 2025.
  • Business Quant data shows Total Current Liabilities for RMD at $1.2 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.0 billion in Q2 2025.